This research study is evaluating an investigational drug for atopic dermatitis (also known as eczema) in adults. You may be able to take part in this research study if you:
Are at least 18 years old
Were diagnosed with atopic dermatitis (also known as eczema) and have had symptoms for at least 1 year
Haven't seen enough improvement from a previous or current atopic dermatitis treatment
The research study involves 20 study visits over the course of up to 1 year and 3 months (66 weeks) and will enroll approximately 80 participants globally.
There are 2 phases in this study. In the first phase, participants are randomly assigned to 1 of 2 groups that will receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no active medicine), both administered as a subcutaneous injection (under the skin). In the second phase, all participants receive the investigational drug.
Participation will last up to 1 year and 3 months (66 weeks), which includes 20 visits to the study clinic.
The investigational drug is a solution administered as a subcutaneous injection (under the skin).
Do not discontinue any medication unless you are advised to do so by the study team or your primary care provider.
There is no cost to you for participating in the research study.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this research study. This does not mean you will not qualify for different research studies.
This research study is evaluating an investigational drug for atopic dermatitis (also known as eczema) in adults. You may be able to take part in this research study if you:
Are at least 18 years old
Were diagnosed with atopic dermatitis (also known as eczema) and have had symptoms for at least 1 year
Haven't seen enough improvement from a previous or current atopic dermatitis treatment
The research study involves 20 study visits over the course of up to 1 year and 3 months (66 weeks) and will enroll approximately 80 participants globally.
There are 2 phases in this study. In the first phase, participants are randomly assigned to 1 of 2 groups that will receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no active medicine), both administered as a subcutaneous injection (under the skin). In the second phase, all participants receive the investigational drug.
Participation will last up to 1 year and 3 months (66 weeks), which includes 20 visits to the study clinic.
The investigational drug is a solution administered as a subcutaneous injection (under the skin).
Do not discontinue any medication unless you are advised to do so by the study team or your primary care provider.
There is no cost to you for participating in the research study.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this research study. This does not mean you will not qualify for different research studies.
You are now leaving TheEmbarkStudy.com and being redirected to a website that is not operated by Clinical Trial Media Inc.